000131504 001__ 131504
000131504 005__ 20240228145604.0
000131504 0247_ $$2doi$$a10.1038/nrc.2017.92
000131504 0247_ $$2pmid$$apmid:29077691
000131504 0247_ $$2ISSN$$a1474-175X
000131504 0247_ $$2ISSN$$a1474-1768
000131504 0247_ $$2altmetric$$aaltmetric:28018090
000131504 037__ $$aDKFZ-2017-06171
000131504 041__ $$aeng
000131504 082__ $$a610
000131504 1001_ $$0P:(DE-He78)d2851af71b2aced0c34d8c71329c3bc5$$aGengenbacher, Nicolas$$b0$$eFirst author$$udkfz
000131504 245__ $$aPreclinical mouse solid tumour models: status quo, challenges and perspectives.
000131504 260__ $$aLondon [u.a.]$$bNature Publ. Group$$c2017
000131504 3367_ $$2DRIVER$$aarticle
000131504 3367_ $$2DataCite$$aOutput Types/Journal article
000131504 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661773337_21383$$xReview Article
000131504 3367_ $$2BibTeX$$aARTICLE
000131504 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131504 3367_ $$00$$2EndNote$$aJournal Article
000131504 520__ $$aOncology research in humans is limited to analytical and observational studies for obvious ethical reasons, with therapy-focused clinical trials being the one exception to this rule. Preclinical mouse tumour models therefore serve as an indispensable intermediate experimental model system bridging more reductionist in vitro research with human studies. Based on a systematic survey of preclinical mouse tumour studies published in eight scientific journals in 2016, this Analysis provides an overview of how contemporary preclinical mouse tumour biology research is pursued. It thereby identifies some of the most important challenges in this field and discusses potential ways in which preclinical mouse tumour models could be improved for better relevance, reproducibility and translatability.
000131504 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000131504 588__ $$aDataset connected to CrossRef, PubMed,
000131504 7001_ $$0P:(DE-He78)1956b17ee4a34a5fdd72287aca7cdc0a$$aSinghal, Mahak$$b1$$udkfz
000131504 7001_ $$0P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aAugustin, Hellmut$$b2$$eLast author$$udkfz
000131504 773__ $$0PERI:(DE-600)2060549-3$$a10.1038/nrc.2017.92$$gVol. 17, no. 12, p. 751 - 765$$n12$$p751 - 765$$tNature reviews / Cancer$$v17$$x1474-1768$$y2017
000131504 909CO $$ooai:inrepo02.dkfz.de:131504$$pVDB
000131504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d2851af71b2aced0c34d8c71329c3bc5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000131504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1956b17ee4a34a5fdd72287aca7cdc0a$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000131504 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000131504 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000131504 9141_ $$y2017
000131504 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000131504 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131504 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000131504 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT REV CANCER : 2015
000131504 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131504 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000131504 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000131504 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131504 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131504 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131504 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131504 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000131504 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000131504 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000131504 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000131504 915__ $$0StatID:(DE-HGF)9930$$2StatID$$aIF >= 30$$bNAT REV CANCER : 2015
000131504 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lA190 Vaskuläre Onkologie und Metastasierung$$x0
000131504 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000131504 980__ $$ajournal
000131504 980__ $$aVDB
000131504 980__ $$aI:(DE-He78)A190-20160331
000131504 980__ $$aI:(DE-He78)L101-20160331
000131504 980__ $$aUNRESTRICTED